SEC Form 4 · accession 0001506916-26-000004
Travere Therapeutics, Inc. · TVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey A Meckler
Director
Period of report
Sep 10, 2026
Accepted (ET)
Sep 11, 2026 · 4:05 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001438533
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 10, 2026 | M | 10,000 | $17.44 | A | 101,500 | D | |
| Common Stock | Sep 10, 2026 | M | 10,000 | $26.52 | A | 111,500 | D | |
| Common StockF2 | Sep 10, 2026 | S | 1,700 | $65.3917 | D | 109,800 | D | |
| Common StockF3 | Sep 10, 2026 | S | 1,200 | $66.15 | D | 108,600 | D | |
| Common StockF4 | Sep 10, 2026 | S | 14,000 | $67.4634 | D | 94,600 | D | |
| Common StockF5 | Sep 10, 2026 | S | 3,100 | $68.088 | D | 91,500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F6 | $17.44 | Sep 10, 2026 | M | 10,000 | D | — | May 17, 2027 | Common Stock | 10,000 | 0 | D |
| Stock option (right to buy)F6 | $26.52 | Sep 10, 2026 | M | 10,000 | D | — | May 9, 2028 | Common Stock | 10,000 | 0 | D |
Explanation of responses
- F1This sale was made pursuant to a written plan adopted on June 11, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person on May 17, 2017, with an expiration date of May 17, 2027, and on May 9, 2018, with an expiration date of May 9, 2028.
- F2The weighted average sale price for the transaction reported was $65.3917, and the range of prices were between $64.835 and $65.81. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- F3The weighted average sale price for the transaction reported was $66.15, and the range of prices were between $65.93 and $66.74. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- F4The weighted average sale price for the transaction reported was $67.4634, and the range of prices were between $66.93 and $67.92. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- F5The weighted average sale price for the transaction reported was $68.088, and the range of prices were between $67.94 and $68.23. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- F6The stock option is fully vested and exercisable.